About Harrow Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.harrow.com/
Frequently Asked Questions
What is the 52-week range for HROW?
The 52-week high is $54.85 and the 52-week low is $28.54.
What is the P/E ratio for HROW?
The P/E ratio data is currently unavailable.
What is the dividend yield for HROW?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -103.86%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -13.51%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 34.60.
Analyst Recommendation Trends
Wall Street analyst consensus for HROW over the last few months:
Latest HROW News
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; andAmerican Academy of Ophthalmology’s (AAO) Annual Meeting, taking place
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Leerink Partners Initiates Coverage On Harrow with Outperform Rating, Announces Price Target of $45
Leerink Partners analyst Daniel Clark initiates coverage on Harrow (NASDAQ:HROW) with a Outperform rating and announces Price Target of $45.
This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Bamco, the advisory arm of Ron Baron’s Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna shares nearly tripled on a positive Phase 3 report. Bamco also […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-14 | Shojaei Amir | -11,250 | $35.96 | $404,550 |
| 2026-08-14 | Shojaei Amir | -11,250 | $40 | $450,000 |
| 2026-08-14 | Shojaei Amir | +11,250 | $35.96 | $404,550 |
| 2026-06-18 | Sternberg Perry J. | +5,248 | - | - |
| 2026-06-18 | Graves Adrienne L | +5,248 | - | - |
| 2026-06-18 | SILVERNAIL LAUREN P | +5,248 | - | - |
| 2026-05-18 | Graves Adrienne L | +1,000 | $31.07 | $31,070 |
| 2026-05-18 | SILVERNAIL LAUREN P | +1,000 | $31 | $31,000 |
| 2026-05-15 | Shojaei Amir | +10,000 | - | - |
| 2026-05-14 | BOLL ANDREW R. | +3,500 | $29.9 | $104,650 |
| 2026-05-14 | BAUM MARK L | +10,000 | $30.2 | $302,000 |
| 2026-03-04 | Opaleye Management Inc. | -4,263 | $39.6721 | $169,122 |
| 2026-03-04 | Opaleye Management Inc. | -134,000 | $39.6721 | $5,316,061 |
| 2026-03-03 | Opaleye Management Inc. | -1,309 | $39.1524 | $51,250 |
| 2026-03-03 | Opaleye Management Inc. | -59,000 | $39.1524 | $2,309,992 |
| 2026-02-27 | Opaleye Management Inc. | -5,000 | $54.18 | $270,900 |
| 2026-01-30 | Sullivan Patrick William | +15,000 | - | - |
| 2026-01-30 | Sullivan Patrick William | +25,000 | - | - |
| 2026-01-06 | Opaleye Management Inc. | -20,000 | $53.3457 | $1,066,914 |
| 2025-12-12 | BOLL ANDREW R. | -60,000 | - | - |
| 2025-12-12 | BOLL ANDREW R. | -26,665 | $47.06 | $1,254,855 |
| 2025-12-12 | BOLL ANDREW R. | +60,000 | $3.95 | $237,000 |
| 2025-12-12 | BAUM MARK L | -180,000 | - | - |
| 2025-12-12 | BAUM MARK L | -79,994 | $47.06 | $3,764,518 |
| 2025-12-12 | BAUM MARK L | +180,000 | $3.95 | $711,000 |